CTOs on the Move

Accumulus

www.accumulus.org

 
Accumulus Synergy is a global, non-profit organization that is developing a transformative data exchange platform that aims to enable enhanced collaboration and efficiency between life sciences organizations and global health authorities, while also affording users the ability to extract dynamic, data-driven insights from knowledge management. Sponsored by leading biopharmaceutical companies, Accumulus Synergy was formed in 2020 to create innovative solutions that can reduce regulatory review times and transform global data exchange. The non-profit company is creating a first-of-its-kind cloud-based platform between the biopharmaceutical industry and health authorities worldwide. The single-platform approach aims to improve speed, transparencies and efficiencies in the ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details
Bill Gibson
 Chief Technology Officer Profile
Christopher Jeschke
 Chief Technology Officer Profile
Marvin Larry
 Chief Information Security Officer Profile

Similar Companies

Eisai

Eisai Inc. is a U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd., a research-based human health care (hhc) company that discovers, develops and markets products throughout the world.

Coastal Medical

Coastal Medical, Inc. is Rhode Islands largest, physician owned and physician governed Primary Care practice, serving patients in RI and southeastern Massachusetts.

Modern Recovery

[et_pb_section fb_built="1" specialty="on" custom_padding_last_edited="on|tablet" _builder_version="4.6.6" _module_preset="default" background_color="#9e9e9e"

Flo Healthcare

Flo Healthcare is a Norcross, GA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Innocrin Pharmaceuticals

Innocrin discovers and develops novel, best-in-class oral inhibitors of CYP17 lyase, a validated enzyme target for the treatment of castration-resistant prostate cancer (CRPC). VT-464 and structurally-related classes of CYP17 inhibitors are wholly owned by Innocrin. CYP17 lyase inhibitors may also have high commercial potential for the treatment of breast cancer as well as non-oncologic syndromes that are due to hormonal excess including endometriosis, polycystic ovary syndrome and congenital adrenal hyperplasia.